Medical Properties Trust: The Worst Is Over
Summarize this article with:
Daniel JonesInvesting Group LeaderFollow5ShareSavePlay(12min)CommentsSummaryMedical Properties Trust remains a "Strong Buy" as tenant issues resolve and growth resumes.MPW trades at a significant discount to peers on EV/EBITDA and price/book, with potential 35%+ upside to book value.Re-tenanting and rent escalations are expected to drive annualized cash rent to $1 billion by 2026.Key risks include high net leverage (10.16x EBITDA) and potential capital misallocation via share buybacks. svetikd/E+ via Getty Images Although I don't own anywhere near as many shares of Medical Properties Trust (MPW) as I have in the past, I am still bullish about the company, and I still find it to be an interesting prospect. Lately, that bullishness has paid off. Since This article was written byDaniel Jones35.99K FollowersFollowDaniel is an avid and active professional investor. He runs Crude Value Insights, a value-oriented newsletter aimed at analyzing the cash flows and assessing the value of companies in the oil and gas space. His primary focus is on finding businesses that are trading at a significant discount to their intrinsic value by employing a combination of Benjamin Graham's investment philosophy and a contrarian approach to the market and the securities therein. Learn more.Analyst’s Disclosure:I/we have a beneficial long position in the shares of MPW either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.Recommended For You